Board of Directors

Brian W. Pusch

Brian W. Pusch has served as Chairman of the Board and sole Chief Executive Officer and President since 2018. From 2012 to 2018 he served as Co-Chief Executive Officer of Microbes. He joined the Board of Directors in 1997.

Brian has been involved in founding, financing and advising technology startup companies for nearly 35 years. In 2016 he co-founded Inozyme Pharma, Inc., which is developing enzyme replacement therapies for diseases of aberrant calcification based on the ENPP family of enzymes. Inozyme closed its Series A venture capital round of $49.5 million in January 2017, subsequently raised an additional $67 million in a Series A2 round and completed its IPO in July 2020.

In 2015 Brian co-founded Quantum Circuits, Inc., the world’s leading company engaged in the development of quantum computer hardware and software. He served as founding President of QCI until December 2017, leading it through closing of its $18.5 million Series A venture capital round in September 2017, and served as a member of the Board of Directors through 2018.

Over the years Brian has been a member of teams that have founded, built and financed a number of successful technology startups, including 5 successful exits ranging from $500 million to $6.8 billion. In 1992 he founded Pusch & Gal, a New York City boutique law firm, after a successful career, first as an associate and then as a partner, of a leading Wall Street law firm.

He also serves on the boards of Evrys Bio, LLC (host-targeted antiviral therapeutics based on sirtuins), InvivoSciences Inc. (3-dimensional tissue derived from induced pluripotent stem cells and used for drug discovery, screening and testing), Xiconic Pharmaceuticals, LLC (ADC oncology therapeutics) Opna-IO, LLC (immuno-oncology).

(A.B. in Interdisciplinary Studies of Economics and Government, The College of William & Mary in Virginia, 1976 (Phi Beta Kappa); J.D., University of Virginia, 1979.)

Lillian W. Chiang, Ph.D., MBA

Lillian Chiang served on the Microbes Board of. Directors from October 2010 to February 2017 and then returned to our Board in December 2018. She serves as President and Chief Executive Office of Evrys Bio, LLC, a company she co-founded in 2013 that is developing host-targeted antiviral therapeutics by targeting sirtuin proteins. Prior to Evrys Bio, Lillian was Vice President of Translational Medicine at Kadmon Corporation. She was responsible for strategy and translation from early discovery through proof of concept in man. Throughout her career she has built from scratch, state-of-the-art technologies, drug discovery & development teams, and businesses at Stanford, Millennium Pharmaceuticals, Purdue Pharma, Aestus Therapeutics, and Kadmon.

At Aestus, she applied her own data mining algorithms to identify drug-repositioning assets to acquire and develop in a virtual pharma environment. Aestus’ successfully advanced it first in-licensed product from novel mechanism of action and therapeutic hypothesis to completion of a Phase 2A human clinical trial in 5 years at a cost of $5 million, funded primarily by government grants. BS, Massachusetts institute of Technology; Ph.D., University of Wisconsin; Post-Doc, Stanford University; MBA, The Wharton School of the University of Pennsylvania. .

Tom Lubinski

Tom Lubinski is currently an Advisory Board Member and Chief Software Architect at Quantum Circuits Inc. Since 2016, he has been overseeing key developments in QCI’s advanced Quantum Computer Control System, working to ensure that a consistent architecture extends to all levels of the software stack involved in a complex quantum computing system. Before this, Tom was the Chief Executive Officer and Chief Technology Officer for a software technology company he founded in 1983, SL Corporation, (Sherrill-Lubinski Corporation).

For 37 years, he led the company through the development and marketing of multiple generations of Real-Time Process Monitoring and Control Systems software products and has been involved in thousands of successful customer deployments of real-time visibility solutions. Before starting SL Corporation, Tom attended the California Institute of Technology and subsequently developed a substantial consulting practice specializing in microprocessor control firmware, object-oriented programming and graphical visualization systems. He has over 40 years of experience in the development of computer hardware systems and software applications.

L. Marc Shegoski

Marc has 38 years of experience building long-lasting relationships with non-profits, foundations, endowments, retirement plans, and high net worth clients. As a UBS Senior Institutional Consultant, a designation held by only 28 of UBS‘s top Institutional Consultants, Marc specializes in asset allocation, manager due diligence, portfolio construction, and trading dynamics.

Marc was a partner in the development of the UBS Institutional Consulting Group, previously named PRIME Asset Consulting at Paine Webber & Kidder Peabody. With deep experience beyond consulting, Marc was a founding partner of a New York Stock Exchange firm, a Director of the Office State Courts Administrator for the State of Missouri and a Consultant to the Special Investigation Commission of the New Jersey Senate.

Marc is a board member of multiple charitable organizations in the greater Princeton-New Brunswick area and an adjunct instructor at Rutgers University and Rider University.